Design, Synthesis, Evaluation and Molecular Docking Studies of Novel Triazole Linked 1,4‐Dihydropyridine‐isatin Scaffolds as Potent Anticancer Agents

Abstract

Abstract A series of novel triazole linked isatin‐dihydropyridine hybrids ( N1 ‐ N15 ) have been synthesized and examined for their anti proliferative activity against human cancer cell lines viz. HeLa, Huh‐7, PC‐3, IMR‐32 and MCF‐7. All of the synthesized hybrids have shown moderate to potent cytotoxicity against all the tested cell lines except IMR‐32. Compounds N1 , N2 and N13 have displayed an enhanced inhibitory potency against Huh‐7 cell line as compared to the standard drug, doxorubicin. Out of the three, N2 has shown the highest in vitro inhibitory action with IC 50 values of 6.73±0.33 μM and 17.94±0.23 μM against Huh‐7 and MCF‐7 cell lines, respectively. The docking studies of these most potent compounds have also been investigated which identified that N2 might be an excellent drug‐like candidate worthy of further pursuit.